Comparative Efficacy and Safety of Glucagon Receptor Agonists on Metabolic Outcomes: A Network Meta-Analysis of Randomised Controlled Trials - PubMed
5 days ago
- #glucagon receptor agonists
- #obesity
- #type 2 diabetes
- Glucagon receptor agonists (GRAs) are emerging therapies for obesity and type 2 diabetes.
- Retatrutide showed the greatest weight reduction (-13.44 kg) compared to placebo.
- Survodutide and mazdutide also demonstrated significant weight loss effects.
- Cotadutide had the smallest and nonsignificant effect on weight reduction.
- Retatrutide was most effective in reducing HbA1c, followed by survodutide, mazdutide, and cotadutide.
- Mazdutide had the best tolerability profile, while retatrutide and cotadutide had lower tolerability.
- Retatrutide and survodutide show the most favorable efficacy for obesity and type 2 diabetes with acceptable safety.